Blue Cell Therapeutics ApS: Financial statements 2023
CVR: 39981610
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Blue Cell Therapeutics ApS (CVR 39981610) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -741,530 and a net result of DKK -15,288,373 compared with DKK -12,569,961 the year before. Equity in the 2023 report amounted to DKK 8,419,035. The solvency ratio was 82.9%. The company had 14 employees in the financial year.
- Gross Profit
- DKK -741,530
- Profit/Loss
- DKK -15,288,373
- Equity
- DKK 8,419,035
- Total Assets
- DKK 10,159,188
- Employees
- 14
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -742K | -15.3M | 8.4M | 14 |
| 2022 | - | 852K | -12.6M | 9.9M | 12 |
| 2021 | - | -844K | -14.2M | 12.5M | 7 |
| 2020 | - | -2.9M | -14M | 9.8M | 2 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
As of October 20, 2023, Anella Rogaczewski has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 24, 2023, Michael Ulveman has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 24, 2023, Ole Vahlgren has joined the board of directors of Blue Cell Therapeutics ApS.
As of August 23, 2023, Michael Ulveman has left the board of directors of Blue Cell Therapeutics ApS.
As of August 23, 2023, Ole Vahlgren has left the board of directors of Blue Cell Therapeutics ApS.
Blue Cell Therapeutics ApS has published its annual report for 2022. Gross profit came to DKK 852,135, and the net result was DKK -12,569,961.
As of January 30, 2023, Casper Tind Hansen has left the board of directors of Blue Cell Therapeutics ApS.
About Blue Cell Therapeutics ApS
Blue Cell Therapeutics ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Regenerative Therapeutics IVS. The management consists of Søren Paludan Sheikh. The board consists of Olav Hellebø (chair), Anella Rogaczewski, Michael Ulveman and Ole Vahlgren. The company is owned by ANDRÉ ROGACZEWSKI HOLDING II ApS and SPSheikh Holding ApS. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -5,780,568 and a net result of DKK -21,221,120 compared with DKK -15,189,850 the year before. Equity in the 2025 report amounted to DKK -8,126,690.